Advertisement

Organisation › Details
Promethera Biosciences S.A.
Promethera is a global innovator in severe liver diseases and the leader in liver cell-based medicines whose mission is to help overcome acute and chronic liver diseases. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immunemodulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies to complement and diversify our therapeutic options. We are a team of international experts operating out of R&D and GMP facilities in Mont-Saint-Guibert, Belgium, and Durham, NC, USA. Promethera®, HepaStem®, H2stem®, Cytonet®, Heparesc® are all registered trademarks of the PROMETHERA group. *
![]() |
Start | 2009-02-12 splitoff |
![]() |
End | 2021-06-30 renamed (reorg)? |
Group | Promethera (Group) | |
Today | Promethera Therapeutics S.A. | |
Predecessor | Université Catholique de Louvain (UCLouvain) | |
Successor | Promethera Therapeutics S.A. | |
![]() |
Industry | HepaStem cell therapy product |
Industry 2 | stem cell technology | |
![]() |
Person | Tchelingerian, John (Promethera 201509– CEO before Silver Ocean Ventures + Neurotech + Diatos) |
Person 2 | Takano, Mutsuki (Promethera 201810– Group CFO joined 7/18 as General Manager Promethera Japan before Mitsui) | |
![]() |
Region | Mont-Saint-Guibert |
Country | Belgium | |
Street | 11 Rue Granbonpré Watson & Crick Hill | |
City | 1435 Mont-Saint-Guibert | |
Tel | +32-10-394300 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2024-06-07 |
Advertisement

More documents for Promethera (Group)
- [1] Promethera Therapeutics S.A.. (6/30/21). "Press Release: Walloon Company Promethera Announces a €20 Million Financing Round". Mont-Saint-Guibert....
- [2] Promethera Biosciences S.A.. (12/16/19). "Press Release: Promethera Attracts Sony Innovation Fund by IGV and Pegasus Tech Ventures as New Investors in Final Closing of Series D . Total Amount Raise in the Series D Reaches €47.2 Million". Mont-Saint-Guib...
- [3] Promethera Biosciences S.A.. (5/7/19). "Press Release: Promethera Biosciences Completes €39.7 Million ($44.4 Million) Series D Financing". Mont-Saint-Guibert & Tokyo....
- [4] Promethera Biosciences S.A.. (1/2/19). "Press Release: Promethera Biosciences Announces Investment by Itochu Corporation and a Broad Strategic Collaboration to Access the Asian Markets". Mont-Saint-Guibert & Tokyo....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top